Keyphrases
Adjuvant Therapy
12%
Allogeneic
11%
Allogeneic Bone Marrow Transplantation
31%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Allogeneic Peripheral Blood Stem Cell Transplantation
15%
Bone Marrow Transplantation
14%
Cetuximab
54%
Chemotherapy
14%
Cisplatin
27%
Clinical Benefit
12%
Clinical Outcomes
15%
Confidence Interval
22%
Cyclophosphamide
15%
Distant Metastasis
15%
Docetaxel
16%
Graft-versus-host Disease (GvHD)
26%
Granulocyte Colony-stimulating Factor (G-CSF)
30%
Hazard Ratio
11%
Head-and-neck
36%
Head-and-neck Cancer
69%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
100%
High-dose Chemotherapy
18%
High-risk Human Papillomavirus (HR-HPV)
54%
Induction Chemotherapy
19%
Locally Advanced
24%
Metastatic Breast Cancer
13%
Nab-paclitaxel
17%
Nasopharyngeal Carcinoma
11%
NCCN Guidelines
11%
Neoadjuvant
13%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
51%
Overall Survival
42%
Palbociclib
14%
Pembrolizumab
19%
Peripheral Blood Stem Cell Transplantation
11%
Peripheral Blood Stem Cells
19%
Phase II Study
31%
Phase II Trial
40%
Progression-free Survival
16%
Radiation Therapy
20%
Randomized Phase II Trial
20%
Recurrent Metastatic
18%
Recurrent or Metastatic
36%
Soft Tissue Sarcoma
12%
Solid Tumors
15%
Squamous Cell Carcinoma of Head
22%
Total Body Irradiation
18%
Transplant Recipients
11%
Tumor
24%
Tumor Response
15%
Medicine and Dentistry
Adjuvant Therapy
11%
Adverse Event
12%
Allogeneic Peripheral Blood Stem Cell Transplantation
9%
Allogenic Bone Marrow Transplantation
11%
Arm
11%
Autologous Stem Cell Transplantation
11%
Biological Marker
11%
Bone Cancer
10%
Breast Cancer
11%
Cancer
12%
Cetuximab
39%
Chronic Myelogenous Leukemia
10%
Cisplatin
23%
Clinical Trial
9%
Conditioning
9%
Connective Tissue Cancer
13%
Disease Free Survival
10%
Diseases
46%
Distant Metastasis
12%
Granulocyte
10%
Granulocyte Colony Stimulating Factor
17%
Hazard Ratio
13%
Head and Neck Cancer
51%
Head and Neck Squamous Cell Carcinoma
73%
Immunotherapy
13%
Induction Chemotherapy
14%
Malignant Neoplasm
13%
Metastatic Breast Cancer
10%
Metastatic Carcinoma
10%
Neck
35%
Neoplasm
50%
Neutrophil
12%
Oncology
9%
Oropharynx Carcinoma
23%
Oropharynx Squamous Cell Carcinoma
35%
Overall Survival
41%
P16
13%
Paclitaxel
15%
Palbociclib
9%
Pembrolizumab
19%
Peripheral Blood Stem Cell
9%
Progression Free Survival
18%
Radiation Therapy
29%
Recurrent Disease
13%
Soft Tissue Sarcoma
15%
Squamous Cell Carcinoma
22%
T Cell
12%
Transplantation
23%
Wart Virus
47%
Whole Body Radiation
10%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
12%
Adverse Event
16%
Alpha Interferon
5%
Antitumor Activity
7%
Biological Marker
8%
Breast Cancer
10%
Carboplatin
5%
Cetuximab
49%
Chemoradiation Therapy
11%
Chemotherapy
30%
Ciclosporin
5%
Cisplatin
22%
Cyclin Dependent Kinase 4
6%
Cyclophosphamide
15%
Dacarbazine
7%
Disease Exacerbation
6%
Diseases
31%
Docetaxel
15%
Doxorubicin
8%
Epidermal Growth Factor Receptor
6%
Fluorouracil
6%
Graft Versus Host Reaction
6%
Granulocyte Colony Stimulating Factor
6%
Granulocyte Macrophage Colony Stimulating Factor
5%
Growth Factor
10%
Head and Neck Cancer
33%
Head and Neck Squamous Cell Carcinoma
69%
High Dose Chemotherapy
14%
Human Papillomavirus
22%
Immunotherapy
9%
Malignant Neoplasm
12%
Metastatic Breast Cancer
10%
Methotrexate
6%
Monotherapy
8%
Nasopharynx Carcinoma
5%
Neoplasm
38%
Neutropenia
10%
Oral Mucositis
8%
Organ Toxicity
7%
Oropharynx Squamous Cell Carcinoma
10%
Overall Survival
38%
Paclitaxel
20%
Palbociclib
14%
Pembrolizumab
13%
Placebo
7%
Progression Free Survival
23%
Remission
11%
Soft Tissue Sarcoma
12%
Solid Malignant Neoplasm
18%
Squamous Cell Carcinoma
26%